Recent from talks
Lenacapavir
Knowledge base stats:
Talk channels stats:
Members stats:
Lenacapavir
Lenacapavir, sold under the brand names Sunlenca among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is taken by mouth or by subcutaneous injection. Lenacapavir is a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor.
The most common side effects include reactions at the injection site and nausea.
Lenacapavir was approved for medical treatment in the European Union in August 2022, in Canada in November 2022, and in the United States in December 2022. It is the first of a class of drugs called capsid inhibitors to be approved by the US Food and Drug Administration for treating HIV/AIDS. In June 2025, lenacapavir, as Yeztugo, received approval in the US for HIV prevention.
Lenacapavir, as Sunlenca, in combination with other antiretrovirals, is indicated for the treatment of HIV/AIDS. It is used in heavily treatment-experienced adults with multiple drug resistance in whom current antiretroviral therapy is ineffective due to resistance, intolerance or safety considerations.
Lenacapavir, (as Yeztugo or Yeytuo), is indicated for pre-exposure prophylaxis for HIV prevention to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing more than 35 kilograms (77 lb) who are at risk for HIV-1 acquisition.
Lenacapavir works by binding directly to the interface between HIV-1 viral capsid protein (p24) subunits in capsid hexamers, interfering with essential steps of viral replication, including capsid-mediated nuclear uptake of HIV-1 proviral DNA (it over-stabilizes the capsid, preventing it from properly releasing its contents), virus assembly and release, production of capsid protein subunits, and capsid core formation. The US Food and Drug Administration considers it to be a first-in-class medication.
Because lenacapavir is the first medication that targets the p24 capsid, mutations that confer resistance to other antiretrovirals have no effect on lenacapavir. However, mutations of the capsid can still confer resistance, especially when the drug is used without an optimized background therapy.
Lenacapavir was developed by Gilead Sciences.
Hub AI
Lenacapavir AI simulator
(@Lenacapavir_simulator)
Lenacapavir
Lenacapavir, sold under the brand names Sunlenca among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is taken by mouth or by subcutaneous injection. Lenacapavir is a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor.
The most common side effects include reactions at the injection site and nausea.
Lenacapavir was approved for medical treatment in the European Union in August 2022, in Canada in November 2022, and in the United States in December 2022. It is the first of a class of drugs called capsid inhibitors to be approved by the US Food and Drug Administration for treating HIV/AIDS. In June 2025, lenacapavir, as Yeztugo, received approval in the US for HIV prevention.
Lenacapavir, as Sunlenca, in combination with other antiretrovirals, is indicated for the treatment of HIV/AIDS. It is used in heavily treatment-experienced adults with multiple drug resistance in whom current antiretroviral therapy is ineffective due to resistance, intolerance or safety considerations.
Lenacapavir, (as Yeztugo or Yeytuo), is indicated for pre-exposure prophylaxis for HIV prevention to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing more than 35 kilograms (77 lb) who are at risk for HIV-1 acquisition.
Lenacapavir works by binding directly to the interface between HIV-1 viral capsid protein (p24) subunits in capsid hexamers, interfering with essential steps of viral replication, including capsid-mediated nuclear uptake of HIV-1 proviral DNA (it over-stabilizes the capsid, preventing it from properly releasing its contents), virus assembly and release, production of capsid protein subunits, and capsid core formation. The US Food and Drug Administration considers it to be a first-in-class medication.
Because lenacapavir is the first medication that targets the p24 capsid, mutations that confer resistance to other antiretrovirals have no effect on lenacapavir. However, mutations of the capsid can still confer resistance, especially when the drug is used without an optimized background therapy.
Lenacapavir was developed by Gilead Sciences.
Recent media